Can sleep affect the progression of Alzheimer’s disease? That’s what a study led by the University of Bristol will explore, thanks to a £4.3 million grant by the Medical Research Council (MRC).
The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality, thanks to a new collaboration between world-leading researchers, including the University of Bristol.
The University of Bristol is one of nine UK universities included in a new £50 million 'Inequalities Challenge Consortium' launched by the National Institute for Health and Care Research (NIHR) to support research into addressing inequalities in cardiovascular disease (CVD) which accounts for 26% of all deaths in the UK.
Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London (UCL).
A new global analysis of two antenatal treatments that reduce the risk of cerebral palsy and respiratory complications in premature babies reveals significant international variation in implementation. The University of Bristol-led study, published in the International Journal of Obstetrics & Gynaecology today [25 February], examined neonatal data from over 300,000 premature births across ten countries.
In the first review of its kind, new research has found that depression and the use of antidepressants are each associated with an increased risk of venous thromboembolism (VTE). The study led by academics from the Musculoskeletal Research Unit at the University of Bristol has also shown that each of the various classes of antidepressant medications are associated with an increased risk of VTE.
Researchers from the Musculoskeletal Research Unit at the University of Bristol have identified the most important risk factors for developing severe infection after hip replacement. Patients who are under 60 years of age, males, those with chronic pulmonary disease, diabetes and a higher body mass index are at increased risk of having the joint replacement redone (known as revision) due to infection. The research also showed that some patients are at risk of early infection whilst others are more prone to late infection after hip replacement.
Antiplatelet drugs such as aspirin have little effect on the need for life support in COVID-19, but they may improve survival in the following months according to a new international study led in the UK by researchers at the University of Bristol and Imperial College London.
Researchers at the University of Bristol are looking for people with an inherited neurological condition called Friedreich's ataxia (FA) to take part in a study into whether a stem cell therapy could be a treatment for FA.
Members of the public still have time to visit an exhibition that brings together art and medicine to reflect on the complexity of the human heart.
